Eli Lilly's (LLY) Retevmo delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Importance
Level 1
#ELI LILLY & CO#LLY.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES